BridgeBio Pharma EBITDA 2018-2024 | BBIO

BridgeBio Pharma EBITDA for the quarter ending September 30, 2024 was $-0.190B, a 21.89% increase year-over-year.

  • BridgeBio Pharma 2023 EBITDA was -0.601B, a 18.88% increase from 2022.
  • BridgeBio Pharma 2022 EBITDA was -0.505B, a 11.45% decline from 2021.
  • BridgeBio Pharma 2021 EBITDA was -0.571B, a 20.67% increase from 2020.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

BridgeBio Pharma EBITDA 2018-2024 | BBIO

  • BridgeBio Pharma 2023 EBITDA was -0.601B, a 18.88% increase from 2022.
  • BridgeBio Pharma 2022 EBITDA was -0.505B, a 11.45% decline from 2021.
  • BridgeBio Pharma 2021 EBITDA was -0.571B, a 20.67% increase from 2020.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
Teva Pharmaceutical Industries (TEVA)$24.9B
Dr Reddy's Laboratories (RDY)$12.6B
Bausch Health Cos (BHC)$2.8B
Supernus Pharmaceuticals (SUPN)$2.1B
Amphastar Pharmaceuticals (AMPH)$1.7B
Personalis (PSNL)$396M
Taysha Gene Therapies (TSHA)$314M
Assembly Biosciences (ASMB)$95M
Sol-Gel Technologies (SLGL)$25M
Evoke Pharma (EVOK)$6M
Teligent (TLGT)$0M